/
Constellium SE, a Societas Europaea ( SE ) incorporated under the law of France with its head office located at Washington Plaza 40-44 rue Washington, Paris, France, is the parent company of the Group. Unless the context indicates otherwise, when we refer to we, our, us, Constellium, the Group and the Company in this document, we are referring to Constellium SE and its subsidiaries.
$28.12
$0.41 (-1.44%)
EOD Jul 17, 2026
Revenue grew 15.2%, still solid.
Net debt of $1.98B represents 12.4x FCF, leverage limits flexibility.
9.1x earnings, 24.8x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$8.93B
▲ +15.2% YoY
Net Income (TTM)
$434M
▲ +387.5% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (FY)
$159M
▲ +242.0% YoY
Op. Cash Flow (FY)
$489M
▲ +62.5% YoY
Net Debt
$1.86B
Cash & Equiv.
$143M
3Y CAGR: -0.3%
3Y CAGR: +27.9%
Continue Research
At a P/E of 9.1 and a price-to-free-cash-flow of 24.8, Constellium (CSTM) trades below a two-stage DCF intrinsic value of about $44.02 per share, so at $28.12 the stock looks undervalued (56.5% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Constellium scores 47/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $44.02 per share for CSTM, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $33.01. At today's $28.12, that puts the stock about 56.5% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Constellium scores 47 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. CSTM currently trades below its estimated intrinsic value and scores 47/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.